title: Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
abstract: OBJECTIVE
  To investigate the correlation between in vitro susceptibility of isolates and clinical outcomes with telithromycin in respiratory tract infections.
  
  
  METHODS
  The activity of telithromycin was determined by in vitro susceptibility testing of key respiratory tract pathogens isolated from patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute maxillary sinusitis enrolled in 14 Phase III/IV clinical trials evaluating the clinical efficacy of telithromycin.
  
  
  RESULTS
  In this pooled analysis, telithromycin mode minimum inhibitory concentration (MIC) and MIC90, respectively, were: 0.016 and 0.03 mg/l against Streptococcus pneumoniae (n=626); 0.03 and 0.5 mg/l for penicillin-resistant S. pneumoniae (n=56); 0.03 and 1 mg/l for erythromycin-resistant S. pneumoniae (n=81); 2 and 4 mg/l against Haemophilus influenzae (including beta-lactamase producers; n=627); both 0.12 mg/l for Moraxella catarrhalis (n=159) and both 0.25 mg/l for Staphylococcus aureus (n=124). Telithromycin (5 or 7-10 days) resulted in overall clinical and bacteriologic success rates of 88.1% (1593/1808) and 89% (1593/1789), respectively.
  
  
  CONCLUSIONS
  High levels of in vitro susceptibility to telithromycin are paralleled by high rates of clinical cure and bacteriologic eradication.
authors.affiliation: Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ont, Canada. dlow@mtsinai.on.ca
authors.forename: Donald E
authors.initials: DE
authors.lastname: Low
authors.forename: David
authors.initials: D
authors.lastname: Felmingham
authors.forename: Steve D
authors.initials: SD
authors.lastname: Brown
authors.forename: Manickam
authors.initials: M
authors.lastname: Rangaraju
authors.forename: Roomi
authors.initials: R
authors.lastname: Nusrat
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001419:Bacteria / Q000187:drug effects*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002908:Chronic Disease; D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D048628:Ketolides; D018942:Macrolides / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D016032:Randomized Controlled Trials as Topic; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D048628:Ketolides; D018942:Macrolides; C106791:telithromycin